Education
About Us
Working with TipRanks
Follow Us
Avidity Biosciences Inc (RNA)
NASDAQ:RNA
RNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.56 - $56.00
Previous CloseN/A
Volume185.29K
Average Volume (3M)1.39M
Market Cap
$3.55B
Enterprise Value$2.24B
Total Cash (Recent Filing)$219.87M
Total Debt (Recent Filing)$6.80M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
May 13, 2025EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.90
Shares Outstanding120,212,300
10 Day Avg. Volume1,564,769
30 Day Avg. Volume1,389,643
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)340.22
Price to Cash Flow (P/CF)-9.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit205.74
Enterprise Value/Ebitda-5.95
Forecast
1Y Price Target
$67.83Price Target Upside153.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessRNA announced they have completed enrollment in the biomarker cohort of the Phase 1/2 FORTITUDE study of delpacibart braxlosiran in facioscapulohumeral muscular dystrophy.
Efficacy And SafetyThe recent data shared by Avidity confirms del-zota’s superior efficacy and safety profile.
Leadership In MarketRNA is seen as the clear leader in the FSHD development space following a competitor's phase 3 failure.
Bears Say
Market CompetitionMinimal impacts expected from recent FDA changes.
Regulatory ApprovalGiven the alignment with FDA on the regulatory path, Avidity is all set for the BLA filing with approval most likely in 2026.
Regulatory ChallengesRNA announced plans to share regulatory updates and topline data in 2Q25, reaffirming their development plan for del-brax with plans to pursue accelerated approval based on this novel circulating biomarker.
---
Ownership Overview
1.57% Insiders
33.65% Mutual Funds
0.15% Other Institutional Investors
49.48% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RNA FAQ
What was Avidity Biosciences Inc’s price range in the past 12 months?
Avidity Biosciences Inc lowest stock price was $21.56 and its highest was $56.00 in the past 12 months.
What is Avidity Biosciences Inc’s market cap?
Avidity Biosciences Inc’s market cap is $3.55B.
When is Avidity Biosciences Inc’s upcoming earnings report date?
Avidity Biosciences Inc’s upcoming earnings report date is May 13, 2025 which is in 40 days.
How were Avidity Biosciences Inc’s earnings last quarter?
Avidity Biosciences Inc released its earnings results on Feb 27, 2025. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.792 by -$0.008.
Is Avidity Biosciences Inc overvalued?
According to Wall Street analysts Avidity Biosciences Inc’s price is currently Undervalued.
Does Avidity Biosciences Inc pay dividends?
Avidity Biosciences Inc does not currently pay dividends.
What is Avidity Biosciences Inc’s EPS estimate?
Avidity Biosciences Inc’s EPS estimate is -0.88.
How many shares outstanding does Avidity Biosciences Inc have?
Avidity Biosciences Inc has 120,212,300 shares outstanding.
What happened to Avidity Biosciences Inc’s price movement after its last earnings report?
Avidity Biosciences Inc reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.792. Following the earnings report the stock price went up 5.365%.
Which hedge fund is a major shareholder of Avidity Biosciences Inc?
Currently, no hedge funds are holding shares in RNA
---
Avidity Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.83 (153.66% Upside)
$67.83 (153.66% Upside)
Blogger Sentiment
Bullish
RNA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 538.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days <0.1%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.28%
12-Months-Change
Fundamentals
Return on Equity
-33.47%
Trailing 12-Months
Asset Growth
148.81%
Trailing 12-Months
Company Description
Avidity Biosciences Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
---
RNA Stock 12 Month Forecast
Average Price Target
$67.83
▲(153.66% Upside)
Technical Analysis
Best Analysts Covering RNA
1 Year
1 Year Success Rate
11/22 ratings generated profit
1 Year Average Return
+113.32%
reiterated a buy rating last month
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +113.32% per trade.
---